What blood or urine tests detect ivermectin and their detection windows?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Blood and urine assays for ivermectin exist, chiefly high-performance liquid chromatography (HPLC) with fluorometric detection and liquid chromatography–tandem mass spectrometry (LC‑MS/MS); plasma/whole‑blood methods have validated ranges down to ~0.97–1 ng/mL [1] [2]. Ivermectin concentrates in tissues and is largely excreted in feces with <1% excreted unchanged in urine, which limits urine detection compared with blood [3] [4] [5].
1. What tests detect ivermectin: lab‑grade HPLC and LC‑MS/MS
Published methods used to measure ivermectin in human samples are laboratory chromatographic assays rather than routine point‑of‑care screens. A reversed‑phase HPLC assay with sensitive fluorometric detection was developed to measure ivermectin in human plasma and urine with a lower limit ~1 ng/mL [2]. More recent work validates LC‑MS/MS assays for ivermectin in plasma and whole blood, giving precise quantitation across a range (0.97–384 ng/mL) and demonstrating stability and low matrix interference [1].
2. Why mass spectrometry is preferred: sensitivity and small sample volumes
Ivermectin is lipophilic and partitions into tissues and skin, producing low plasma/blood concentrations; therefore analytical sensitivity matters. Authors note relatively few assays use mass spectrometry for sensitive quantification from small sample volumes, and LC‑MS/MS offers that sensitivity and specificity [1]. HPLC‑fluorometry can reach ~1 ng/mL but LC‑MS/MS methods can be optimized for sub‑ng/mL detection [2] [1].
3. Detection windows: blood vs urine depend on distribution and excretion
Pharmacokinetic reviews state ivermectin is distributed heavily into tissues and skin and eliminated mainly in feces; less than 1% of the administered dose appears unchanged in urine, limiting urine as a matrix for detection [1] [3] [4]. One HPLC study measured plasma concentrations up to 56 hours and attempted urine up to 72 hours after single doses, finding no or very low levels in urine in several reports [2] [5]. Thus blood/plasma sampling is the more reliable route for detection beyond very short times after dosing [2] [5].
4. Practical detection window estimates from available reports
Clinical pharmacology data show measurable plasma concentrations in the day following dosing: an HPLC study reported measurable plasma up to about 56 hours after a single 6–12 mg oral dose, with elimination half‑lives reported near ~12–13 hours [2]. Tissue retention (fat, skin) and enterohepatic recycling extend drug presence in the body, but plasma levels decline with that half‑life, meaning sensitive assays may detect ivermectin in plasma for a few days post‑dose; urine is much less reliable because <1% is excreted unchanged [2] [3] [4].
5. Limitations and what the sources do not say
Available sources do not give a single standardized "detection window" in clinical practice for all assays or specify detection times for LC‑MS/MS in urine because excretion is predominantly fecal and reports vary (not found in current reporting). Sources do not describe routine commercial urine immunoassays for ivermectin comparable to common workplace drug panels; typical workplace/clinical drug screens target substances with higher urinary excretion [6] [7]. No source in the set provides a consensus cutoff or guideline for forensic toxicology detection windows for ivermectin specifically (not found in current reporting).
6. Alternative viewpoints and implications for testing policy
Laboratory studies show detection is technically feasible with sensitive chromatographic methods [1] [2]. Pharmacokinetic literature cautions that tissue sequestration and fecal elimination make urine a suboptimal matrix and limit the timeframe for reliable detection in blood to days rather than weeks [3] [5] [4]. For clinical or forensic needs, this implies choosing LC‑MS/MS on plasma/whole blood with validated limits of quantification rather than relying on urine immunoassays or routine drug panels [1] [2] [6].
7. How to proceed if you need testing now
Clinical or forensic laboratories capable of LC‑MS/MS or HPLC‑fluorometric assays can measure ivermectin in plasma/whole blood; specify the required sensitivity (~1 ng/mL or better) and provide timing of last dose to the lab, because pharmacokinetics (half‑life ~12–13 hours in one study) affect interpretation [2] [1]. If you need commercial test availability, local toxicology labs or hospital reference labs should be queried because standard urine drug panels do not commonly include ivermectin (not found in current reporting; [1]2).
Sources cited: assay validation and LC‑MS/MS methods [1]; HPLC fluorometric assay and plasma/urine data [2]; excretion and distribution/pharmacokinetics [3] [5] [4]; context on matrices and typical drug testing practices [6] [7].